+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.

Age: 42Days - 98DaysAll GendersPhase 3
78 locations
P

Actively Recruiting

Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.

All AgesAll Genders
30 locations
E

Actively Recruiting

This research aims to evaluate the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people recently implanted with this device for resistant hypertension. The study observes patients implanted under the CE-Marked indication to assess how the therapy works in a commercial setting. The registry includes participants implanted within the past 30 days who meet specific blood pressure and medication resistance criteria. Participants in this registry have the BAROSTIM NEO System implanted and are followed over time without additional treatment interventions, as this is an observational study. Data are collected from standard medical care measurements taken before implantation, at enrollment, and at 3, 6, and 12 months after implantation. After the first year, data collection continues every six months for up to three years, providing long-term observation of therapy impact. During the study, participants undergo regular assessments of blood pressure, changes in cardiovascular medications, and health care use from before implant through three years post-implant. Researchers collect this information during routine care visits, and participants remain under usual medical supervision. The total participation duration can be up to three years from implantation, with data collected at scheduled intervals to monitor the therapys ongoing effects.

All AgesAll Genders
26 locations